サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1588830

ゴナドトロピン放出ホルモン（GnRH）アゴニストの世界市場レポート 2024年

Gonadotropin-Releasing Hormone (GnRH) Agonist Global Market Report 2024
出版日: | 発行: The Business Research Company | ページ情報: 英文 175 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=150.82円
ゴナドトロピン放出ホルモン（GnRH）アゴニストの世界市場レポート 2024年
出版日: 2024年11月11日
発行: The Business Research Company
ページ情報: 英文 175 Pages
納期: 2～10営業日
ご注意事項 :
本レポートの納品は、最新情報反映のため受注時に適宜更新しお届けいたします。
更新情報の反映作業にあたり納期もレポート毎に異なりますので、ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

ゴナドトロピン放出ホルモン（GnRH）アゴニストの市場規模は、今後数年間で安定した成長が見込まれます。2028年にはCAGR2.9％で46億米ドルに成長します。予測期間の成長は、認知度の向上と早期診断、ヘルスケア支出の増加、不妊治療におけるGnRHアゴニストの使用の増加、個別化医療に対する需要の高まり、研究資金と助成金の増加などに起因すると考えられます。予想される主な動向としては、ドラッグデリバリーシステムの進歩、腫瘍学および生殖医療における進歩、ホルモン療法の選択肢に対する需要の高まり、研究開発努力の増加、長時間作用型製剤の台頭などが挙げられます。

ホルモン関連疾患の有病率の上昇は、今後数年間のゴナドトロピン放出ホルモン（GnRH）アゴニスト市場の成長を牽引すると予想されます。ホルモン関連疾患は、ホルモン産生を調節する内分泌系の不均衡や機能不全に起因する病状です。これらの疾患には、糖尿病、甲状腺機能亢進症、前立腺がんなどの疾患が含まれます。環境の影響、肥満、メタボリックシンドローム、遺伝、高齢化などの要因が、これらの疾患の発生率の増加に寄与しています。GnRHアゴニストはホルモンレベルの管理に役立ち、ホルモンバランスの乱れやホルモン依存性疾患に関連した問題の治療に的を絞ったアプローチを提供します。例えば、米国疾病予防管理センター（CDC）が2024年6月に発表した報告書によると、2021年には米国で新たに236,659人の前立腺がん患者が発生し、2022年には33,363人が前立腺がんで死亡しています。このように、ホルモン関連疾患の有病率の増加が、GnRHアゴニストの需要を促進しています。

GnRHアゴニスト市場の企業は、ホルモン感受性がんの治療効果と精度を向上させるため、先進アンドロゲン除去療法（ADT）薬の開発に注力しています。GnRHアナログを含むADT治療薬は、アンドロゲンレベルを低下または除去することにより作用し、ホルモン感受性がんの成長を遅らせたり止めたりします。例えば、2024年1月、インドの製薬会社ザイダス・ライフサイエンシズ社は、レルゴリクスをレキシゴのブランド名で発売しました。これは、進行前立腺がんにおけるテストステロン抑制のためのインド初で唯一の1日1回経口療法であり、注射治療の必要性をなくすものです。世界的に認められた有効成分であるレルゴリックスは、迅速なテストステロン抑制効果を発揮します。レキシゴは、インドの進行性前立腺がんに対する既存の注射療法よりも50％手頃な価格で、患者やヘルスケアプロバイダーに安全で効果的かつ利便性の高い治療選択肢を提供することで、前立腺がん治療に大きな進歩をもたらします。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

  • 高インフレが市場に与える影響
  • ウクライナ・ロシア戦争が市場に与える影響
  • COVID-19による市場への影響

第5章 世界の市場規模と成長

  • 世界のゴナドトロピン放出ホルモン（GnRH）アゴニスト市場：促進要因と抑制要因
    • 市場促進要因
    • 市場抑制要因
  • 世界のゴナドトロピン放出ホルモン（GnRH）アゴニスト市場の実績：規模と成長, 2018-2023
  • 世界のゴナドトロピン放出ホルモン（GnRH）アゴニスト市場の予測：規模と成長, 2023-2028, 2033F

第6章 市場セグメンテーション

  • 世界のゴナドトロピン放出ホルモン（GnRH）アゴニスト市場：タイプ別、実績と予測, 2018-2023, 2023-2028F, 2033F
  • リュープロレリン
  • ゴセレリン
  • タルチレリン
  • ヒストレリン
  • その他のタイプ
  • 世界のゴナドトロピン放出ホルモン（GnRH）アゴニスト市場：処方別、実績と予測, 2018-2023, 2023-2028F, 2033F
  • 注射可能
  • インプラント
  • 経口
  • 鼻スプレー
  • 世界のゴナドトロピン放出ホルモン（GnRH）アゴニスト市場：流通チャネル別、実績と予測, 2018-2023, 2023-2028F, 2033F
  • 病院薬局
  • 小売薬局
  • オンライン薬局
  • 世界のゴナドトロピン放出ホルモン（GnRH）アゴニスト市場：用途別、実績と予測, 2018-2023, 2023-2028F, 2033F
  • 前立腺がん
  • 乳がん
  • 子宮内膜症
  • 子宮筋腫
  • 早熟性思春期
  • 不妊治療
  • その他の用途
  • 世界のゴナドトロピン放出ホルモン（GnRH）アゴニスト市場：エンドユーザー別、実績と予測, 2018-2023, 2023-2028F, 2033F
  • 病院
  • 専門クリニック
  • 外来手術センター（ASC）
  • その他のエンドユーザー

第7章 地域別・国別分析

  • 世界のゴナドトロピン放出ホルモン（GnRH）アゴニスト市場：地域別、実績と予測, 2018-2023, 2023-2028F, 2033F
  • 世界のゴナドトロピン放出ホルモン（GnRH）アゴニスト市場：国別、実績と予測, 2018-2023, 2023-2028F, 2033F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • ゴナドトロピン放出ホルモン（GnRH）アゴニスト市場：競合情勢
  • ゴナドトロピン放出ホルモン（GnRH）アゴニスト市場：企業プロファイル
    • Pfizer Inc.
    • AbbVie Inc.
    • Takeda Pharmaceutical Company Limited
    • Sandoz Group AG
    • Ipsen Pharma

第31章 その他の大手企業と革新的企業

  • Aurobindo Pharma Limited
  • Cipla Limited
  • Dr Reddy's Laboratories Ltd.
  • Intas Pharmaceuticals Ltd.
  • Ferring Pharmaceuticals
  • Amneal Pharmaceuticals Inc.
  • Endo International plc
  • Lupin Limited
  • Gland Pharma Limited
  • Glenmark Pharmaceuticals Ltd.
  • Zydus Lifesciences Limited
  • Bachem Holding AG
  • Tolmar Pharmaceuticals Inc.
  • Debiopharm Group
  • Sun Pharmaceutical Industries Ltd.

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の見通しと潜在的な分析

第36章 付録

目次
Product Code: r20112

Gonadotropin-releasing hormone (GnRH) agonists are synthetic drugs that mimic the action of natural GnRH, stimulating the pituitary gland to release follicle-stimulating hormone (FSH) and luteinizing hormone (LH). These agents are employed to manage hormonal imbalances by regulating hormone levels and are particularly valuable in fertility treatments, where they help control and prevent premature ovulation during procedures such as in vitro fertilization.

The main types of GnRH agonists include leuprorelin, goserelin, taltirelin, histrelin, and others. Leuprorelin, a synthetic hormone, is used to treat prostate cancer, endometriosis, and uterine fibroids by decreasing hormone production. It is administered via monthly or quarterly injections and comes in various formulations, such as injectables, implants, oral tablets, and nasal sprays. Distribution channels for these medications include hospital pharmacies, retail pharmacies, and online pharmacies. Applications of leuprorelin encompass prostate cancer, breast cancer, endometriosis, uterine fibroids, precocious puberty, and fertility treatments, with end users including hospitals, specialty clinics, ambulatory surgical centers (ASCs), and other medical facilities.

The gonadotropin-releasing hormone (GnRH) agonists market research report is one of a series of new reports from The Business Research Company that provides gonadotropin-releasing hormone (GnRH) agonists market statistics, including the gonadotropin-releasing hormone (GnRH) agonists industry global market size, regional shares, competitors with the gonadotropin-releasing hormone (GnRH) agonists market share, detailed gonadotropin-releasing hormone (GnRH) agonists market segments, market trends, and opportunities, and any further data you may need to thrive in the gonadotropin-releasing hormone (GnRH) agonists industry. These gonadotropin-releasing hormone (GnRH) agonists market research reports deliver a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The gonadotropin-releasing hormone (GnRH) agonist market size has grown steadily in recent years. It will grow from $3.99 billion in 2023 to $4.1 billion in 2024 at a compound annual growth rate (CAGR) of 2.7%. The growth in the historic period can be attributed to increasing awareness and diagnosis of hormonal disorders, a rising prevalence of hormone-related diseases, a growing incidence of prostate cancer, heightened awareness about hormone therapy, and a greater demand for long-term safety and efficacy.

The gonadotropin-releasing hormone (GnRH) agonist market size is expected to see steady growth in the next few years. It will grow to $4.6 billion in 2028 at a compound annual growth rate (CAGR) of 2.9%. The growth in the forecast period can be attributed to increased awareness and early diagnosis, rising healthcare expenditure, growing use of GnRH agonists in fertility treatments, a heightened demand for personalized medicine, and more research funding and grants. Major trends expected include advancements in drug delivery systems, progress in oncology and reproductive medicine, a growing demand for hormone therapy options, increased research and development efforts, and the rise of long-acting formulations.

The rising prevalence of hormone-related diseases is anticipated to drive the growth of the gonadotropin-releasing hormone (GnRH) agonist market in the coming years. Hormone-related disorders are medical conditions resulting from imbalances or malfunctions in the endocrine system, which regulates hormone production. These disorders include conditions such as diabetes, hyperthyroidism, and prostate cancer. Factors such as environmental influences, obesity, metabolic syndrome, genetics, and an aging population contribute to the increasing incidence of these diseases. GnRH agonists help manage hormone levels and offer a targeted approach to treating issues associated with hormonal imbalances and hormone-dependent conditions. For instance, a report by the Centers for Disease Control and Prevention (CDC) in June 2024 revealed that in 2021, there were 236,659 new cases of prostate cancer in the U.S., with 33,363 deaths from the disease in 2022. Thus, the growing prevalence of hormone-related diseases is fueling the demand for GnRH agonists.

Companies in the GnRH agonist market are focusing on developing advanced androgen deprivation therapy (ADT) drugs to improve treatment efficacy and precision for hormone-sensitive cancers. ADT drugs, including GnRH analogs, work by reducing or eliminating androgen levels, thereby slowing or stopping the growth of hormone-sensitive cancers. For example, in January 2024, Zydus Lifesciences Limited, an India-based pharmaceutical company, introduced Relugolix under the brand name Rexigo. This is India's first and only once-daily oral therapy for testosterone suppression in advanced prostate cancer, eliminating the need for injectable treatments. Relugolix, a globally recognized active ingredient, provides rapid testosterone suppression. Rexigo is 50% more affordable than existing injectable treatments for advanced prostate cancer in India, marking a significant advancement in prostate cancer care by offering a safe, effective, and convenient treatment option for patients and healthcare providers.

In February 2022, Debiopharm, a Switzerland-based manufacturer of GnRH agonists, partnered with Aspen Holdings to launch Trelstar in South Africa. This collaboration aims to introduce Trelstar as a treatment for locally advanced and metastatic hormone-dependent prostate cancer. The partnership is set to deliver a high-quality oncology product, significantly enhancing prostate cancer treatment in the region and improving the overall treatment landscape for affected patients. Aspen Holdings, based in South Africa, provides specialty and generic pharmaceuticals.

Major companies operating in the gonadotropin-releasing hormone (GnRH) agonist market are Pfizer Inc., AbbVie Inc., Takeda Pharmaceutical Company Limited, Sandoz Group AG, Ipsen Pharma, Aurobindo Pharma Limited, Cipla Limited, Dr Reddy's Laboratories Ltd., Intas Pharmaceuticals Ltd., Ferring Pharmaceuticals, Amneal Pharmaceuticals Inc., Endo International plc, Lupin Limited, Gland Pharma Limited, Glenmark Pharmaceuticals Ltd., Zydus Lifesciences Limited, Bachem Holding AG, Tolmar Pharmaceuticals Inc., Debiopharm Group, Sun Pharmaceutical Industries Ltd.

North America was the largest region in the gonadotropin-releasing hormone (GnRH) agonist market in 2023. The regions covered in the gonadotropin-releasing hormone (GnRH) agonist market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the gonadotropin-releasing hormone (GnRH) agonist market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The gonadotropin-releasing hormone (GnRH) agonists market consists of sales of triptorelin, buserelin, and nafarelin. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Gonadotropin-Releasing Hormone (GnRH) Agonist Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on gonadotropin-releasing hormone (GnRH) agonist market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for gonadotropin-releasing hormone (GnRH) agonist ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The gonadotropin-releasing hormone (GnRH) agonist market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of COVID-19 on supply chains and consumption patterns.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Type: Leuprorelin; Goserelin; Taltirelin; Histrelin; Other Types
  • 2) By Formulation: Injectable; Implants; Oral; Nasal Sprays
  • 3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
  • 4) By Application: Prostate Cancer; Breast Cancer; Endometriosis; Uterine Fibroids; Precocious Puberty; Fertility Treatment; Other Applications
  • 5) By End-User: Hospital; Specialty Clinics; Ambulatory Surgical Centers (ASCs); Other End-Users
  • Companies Mentioned: Pfizer Inc.; AbbVie Inc.; Takeda Pharmaceutical Company Limited; Sandoz Group AG; Ipsen Pharma
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Gonadotropin-Releasing Hormone (GnRH) Agonist Market Characteristics

3. Gonadotropin-Releasing Hormone (GnRH) Agonist Market Trends And Strategies

4. Gonadotropin-Releasing Hormone (GnRH) Agonist Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On The Market
  • 4.2. Ukraine-Russia War Impact On The Market
  • 4.3. COVID-19 Impact On The Market

5. Global Gonadotropin-Releasing Hormone (GnRH) Agonist Market Size and Growth

  • 5.1. Global Gonadotropin-Releasing Hormone (GnRH) Agonist Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global Gonadotropin-Releasing Hormone (GnRH) Agonist Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global Gonadotropin-Releasing Hormone (GnRH) Agonist Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Gonadotropin-Releasing Hormone (GnRH) Agonist Market Segmentation

  • 6.1. Global Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Leuprorelin
  • Goserelin
  • Taltirelin
  • Histrelin
  • Other Types
  • 6.2. Global Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Formulation, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Injectable
  • Implants
  • Oral
  • Nasal Sprays
  • 6.3. Global Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • 6.4. Global Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Prostate Cancer
  • Breast Cancer
  • Endometriosis
  • Uterine Fibroids
  • Precocious Puberty
  • Fertility Treatment
  • Other Applications
  • 6.5. Global Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hospital
  • Specialty Clinics
  • Ambulatory Surgical Centers (ASCs)
  • Other End-Users

7. Gonadotropin-Releasing Hormone (GnRH) Agonist Market Regional And Country Analysis

  • 7.1. Global Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Gonadotropin-Releasing Hormone (GnRH) Agonist Market

  • 8.1. Asia-Pacific Gonadotropin-Releasing Hormone (GnRH) Agonist Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Formulation, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.4. Asia-Pacific Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Gonadotropin-Releasing Hormone (GnRH) Agonist Market

  • 9.1. China Gonadotropin-Releasing Hormone (GnRH) Agonist Market Overview
  • 9.2. China Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Formulation, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.4. China Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Gonadotropin-Releasing Hormone (GnRH) Agonist Market

  • 10.1. India Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Formulation, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Gonadotropin-Releasing Hormone (GnRH) Agonist Market

  • 11.1. Japan Gonadotropin-Releasing Hormone (GnRH) Agonist Market Overview
  • 11.2. Japan Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Formulation, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.4. Japan Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Gonadotropin-Releasing Hormone (GnRH) Agonist Market

  • 12.1. Australia Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Formulation, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Gonadotropin-Releasing Hormone (GnRH) Agonist Market

  • 13.1. Indonesia Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Formulation, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Gonadotropin-Releasing Hormone (GnRH) Agonist Market

  • 14.1. South Korea Gonadotropin-Releasing Hormone (GnRH) Agonist Market Overview
  • 14.2. South Korea Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Formulation, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.4. South Korea Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Gonadotropin-Releasing Hormone (GnRH) Agonist Market

  • 15.1. Western Europe Gonadotropin-Releasing Hormone (GnRH) Agonist Market Overview
  • 15.2. Western Europe Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Formulation, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.4. Western Europe Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Gonadotropin-Releasing Hormone (GnRH) Agonist Market

  • 16.1. UK Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Formulation, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Gonadotropin-Releasing Hormone (GnRH) Agonist Market

  • 17.1. Germany Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Formulation, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Gonadotropin-Releasing Hormone (GnRH) Agonist Market

  • 18.1. France Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.2. France Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Formulation, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.3. France Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Gonadotropin-Releasing Hormone (GnRH) Agonist Market

  • 19.1. Italy Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.2. Italy Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Formulation, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.3. Italy Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Gonadotropin-Releasing Hormone (GnRH) Agonist Market

  • 20.1. Spain Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.2. Spain Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Formulation, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.3. Spain Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Gonadotropin-Releasing Hormone (GnRH) Agonist Market

  • 21.1. Eastern Europe Gonadotropin-Releasing Hormone (GnRH) Agonist Market Overview
  • 21.2. Eastern Europe Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Formulation, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.4. Eastern Europe Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Gonadotropin-Releasing Hormone (GnRH) Agonist Market

  • 22.1. Russia Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Formulation, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Gonadotropin-Releasing Hormone (GnRH) Agonist Market

  • 23.1. North America Gonadotropin-Releasing Hormone (GnRH) Agonist Market Overview
  • 23.2. North America Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Formulation, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.4. North America Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Gonadotropin-Releasing Hormone (GnRH) Agonist Market

  • 24.1. USA Gonadotropin-Releasing Hormone (GnRH) Agonist Market Overview
  • 24.2. USA Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Formulation, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.4. USA Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Gonadotropin-Releasing Hormone (GnRH) Agonist Market

  • 25.1. Canada Gonadotropin-Releasing Hormone (GnRH) Agonist Market Overview
  • 25.2. Canada Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Formulation, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.4. Canada Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Gonadotropin-Releasing Hormone (GnRH) Agonist Market

  • 26.1. South America Gonadotropin-Releasing Hormone (GnRH) Agonist Market Overview
  • 26.2. South America Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Formulation, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.4. South America Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Gonadotropin-Releasing Hormone (GnRH) Agonist Market

  • 27.1. Brazil Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Formulation, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Gonadotropin-Releasing Hormone (GnRH) Agonist Market

  • 28.1. Middle East Gonadotropin-Releasing Hormone (GnRH) Agonist Market Overview
  • 28.2. Middle East Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Formulation, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.4. Middle East Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Gonadotropin-Releasing Hormone (GnRH) Agonist Market

  • 29.1. Africa Gonadotropin-Releasing Hormone (GnRH) Agonist Market Overview
  • 29.2. Africa Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Formulation, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.4. Africa Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Gonadotropin-Releasing Hormone (GnRH) Agonist Market Competitive Landscape And Company Profiles

  • 30.1. Gonadotropin-Releasing Hormone (GnRH) Agonist Market Competitive Landscape
  • 30.2. Gonadotropin-Releasing Hormone (GnRH) Agonist Market Company Profiles
    • 30.2.1. Pfizer Inc.
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1.4. Financial Performance
    • 30.2.2. AbbVie Inc.
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2.4. Financial Performance
    • 30.2.3. Takeda Pharmaceutical Company Limited
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3.4. Financial Performance
    • 30.2.4. Sandoz Group AG
      • 30.2.4.1. Overview
      • 30.2.4.2. Products and Services
      • 30.2.4.3. Strategy
      • 30.2.4.4. Financial Performance
    • 30.2.5. Ipsen Pharma
      • 30.2.5.1. Overview
      • 30.2.5.2. Products and Services
      • 30.2.5.3. Strategy
      • 30.2.5.4. Financial Performance

31. Gonadotropin-Releasing Hormone (GnRH) Agonist Market Other Major And Innovative Companies

  • 31.1. Aurobindo Pharma Limited
  • 31.2. Cipla Limited
  • 31.3. Dr Reddy's Laboratories Ltd.
  • 31.4. Intas Pharmaceuticals Ltd.
  • 31.5. Ferring Pharmaceuticals
  • 31.6. Amneal Pharmaceuticals Inc.
  • 31.7. Endo International plc
  • 31.8. Lupin Limited
  • 31.9. Gland Pharma Limited
  • 31.10. Glenmark Pharmaceuticals Ltd.
  • 31.11. Zydus Lifesciences Limited
  • 31.12. Bachem Holding AG
  • 31.13. Tolmar Pharmaceuticals Inc.
  • 31.14. Debiopharm Group
  • 31.15. Sun Pharmaceutical Industries Ltd.

32. Global Gonadotropin-Releasing Hormone (GnRH) Agonist Market Competitive Benchmarking

33. Global Gonadotropin-Releasing Hormone (GnRH) Agonist Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Gonadotropin-Releasing Hormone (GnRH) Agonist Market

35. Gonadotropin-Releasing Hormone (GnRH) Agonist Market Future Outlook and Potential Analysis

  • 35.1 Gonadotropin-Releasing Hormone (GnRH) Agonist Market In 2028 - Countries Offering Most New Opportunities
  • 35.2 Gonadotropin-Releasing Hormone (GnRH) Agonist Market In 2028 - Segments Offering Most New Opportunities
  • 35.3 Gonadotropin-Releasing Hormone (GnRH) Agonist Market In 2028 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer